Gene Therapy Approaches to Replace or Restore Dystrophin PF-06939926 – Kasia Lobello, MD (Pfizer, Inc.) RGX-202 – Jahannaz Dastgir, DO (REGENXBIO) scAAV9.U7-ACCA – Kevin Flanigan, MD (Nationwide Children’s Hospital) SGT-001 – Carl Morris, PhD (Solid Biosciences) SRP-9001 – Teji Singh, MD (Sarepta Therapeutics) 2022 PPMD Annual Conference,Conferences & Meetings 2 years ago You may also like 21:06 Capricor Therapeutics 4 years ago Conferences & Meetings,In the Pipeline: Combating Fibrosis & Inflammation 18:40 Sarepta Therapeutics 4 years ago Conferences & Meetings,In the Pipeline: Gene Therapy gene therapy 17:20 Pfizer Inc. 4 years ago Conferences & Meetings,In the Pipeline: Gene Therapy gene therapy 21:45 Audentes Therapeutics 4 years ago Conferences & Meetings,In the Pipeline: Gene Therapy gene therapy 19:10 Solid Biosciences 4 years ago Conferences & Meetings,In the Pipeline: Gene Therapy gene therapy 13:05 Astellas Pharma 4 years ago Conferences & Meetings,In the Pipeline: Downstream Targets 12:31 Santhera Pharmaceuticals 4 years ago Conferences & Meetings,In the Pipeline: Downstream Targets 10:23 Cumberland Pharmaceuticals 4 years ago Conferences & Meetings,In the Pipeline: Downstream Targets «1…1819202122…25»Page 20 of 25
by: Parent Project Muscular Dystrophy
